Mifepristone in abortion care

Courtney Schreiber, Mitchell D Creinin

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

With the addition of a prostaglandin analog, mifepristone allows for successful outpatient termination of pregnancy up to 63 days gestation in 92-99% of women. In the inpatient setting, studies have shown that mifepristone in combination with a prostaglandin analog is also effective as an abortifacient in the late first trimester. In the second trimester, the addition of mifepristone to a prostaglandin regimen has been shown to expedite induction time. At all stages of pregnancy, the use of mifepristone facilitates and ameliorates prostaglandins' expulsive effects on the uterine contents. The rich literature regarding mifepristone in the setting of abortion care has made an important contribution to how physicians treat undesired and problem pregnancies. As with any area of medicine, treatment options provide important flexibility for patients and clinicians alike.

Original languageEnglish (US)
Pages (from-to)82-91
Number of pages10
JournalSeminars in Reproductive Medicine
Volume23
Issue number1
DOIs
StatePublished - Feb 2005
Externally publishedYes

Keywords

  • Medical abortion
  • Mifepristone
  • Misoprostol

ASJC Scopus subject areas

  • Endocrinology
  • Physiology
  • Obstetrics and Gynecology
  • Reproductive Medicine

Fingerprint Dive into the research topics of 'Mifepristone in abortion care'. Together they form a unique fingerprint.

  • Cite this